AUTHOR=Mahajan Abhishek , Unde Himangi , Sable Nilesh P. , Shukla Shreya , Vaish Richa , Patil Vijay , Agarwal Ujjwal , Agrawal Archi , Noronha Vanita , Joshi Amit , Kapoor Akhil , Menon Nandini , Agarwal Jai Prakash , Laskar Sarbani Ghosh , Dcruz Anil Keith , Chaturvedi Pankaj , Pai Prathamesh , Rane Swapnil Ulhas , Bal Munita , Patil Asawari , Prabhash Kumar 

TITLE=Response assessment of post-treatment head and neck cancers to determine further management using NI-RADS (Neck Imaging Reporting and Data System): a subgroup analysis of a randomized controlled trial

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1200366

DOI=10.3389/fonc.2023.1200366

ISSN=2234-943X

ABSTRACT=Objective: Interpreting complex post-treatment changes in head and neck cancer (HNC) is challenging with further added perplexity due to variable interobserver interpretation and hence evolved the NI-RADS lexicon. We evaluated the accuracy of NI-RADS in predicting disease status on 1st post-treatment follow-up CECT in a homogenous cohort of those who received only chemoradiation.
Methods:  Retrospective analysis of imaging was done for LASHNC patients who received radical chemoradiation in an open-label, investigator-initiated, phase 3 randomized trial (2012-2018) randomly assigned to either radical radiotherapy with concurrent weekly cisplatin (CRT) or CRT with the same schedule plus weekly nimotuzumab (NCRT). 536 patients were accrued, and 74 patients who did not undergo PET/CECT after 8 weeks post-CRT were excluded. After assessing 462 patients for eligibility to allocate NI-RADS at primary and node sites, 435 cases in the Primary cohort and 412 cases in Node cohort. We evaluated sensitivity, specificity, disease prevalence, the positive and negative predictive value of the NI-RADS lexicon as well as accuracy which were expressed as percentages. 
Results: Out of 435 primary cohort, 92%, 55%, 48% ,70% were concordant and had 100%, 72%, 70%, 82% accuracy in NI-RADS1 (n=12), NI-RADS2 (n=261), NI-RADS3 (n=105), and NI-RADS 4 (n=60) respectively. Out of 412 nodes cohort, 95%, 90%, 48%, 70%were concordant and had 92%, 97%, 90%, 67% accuracy in NI-RADS1 (n=57), NI-RADS2 (n=255), NI-RADS3 (n=105) and NI-RADS4 (n=60) respectively. % concordance of PET/CT and CECT across all primary and node cohorts revealed that PET/CT was 91% concordant in primary NI-RADS2 as compared to 55% concordance of CECT whereas concordance of CECT was better with 57% in primary NI-RADS3 cohort as compared to PET/CT concordance of 41%.
Conclusions: The accuracy with which the NI-RADS lexicon performed in our study at node sites was better than that at the primary site. There is a great scope of research to understand if CECT performs better over clinical disease status in NI-RADS 3 and 4 categories. Further research should be carried out to understand if PET/CECT can be used for close interval follow-up in stage III/IV NI-RADS 2 cases.